08/01/1994 - "Overall, studies represented a wide range of research and commercial situations demonstrating that sometribove had no effect on incidence of clinical mastitis during the lactation of treatment. "
08/01/1994 - "Furthermore, sometribove did not alter typical relationships between milk yield or herd factors and incidence of clinical mastitis."
08/01/1994 - "No effect on clinical mastitis was observed in 70 commercial herds utilizing sometribove for 84 d. "
08/01/1994 - "When expressed per unit of milk, mastitis incidence declined slightly as milk yield increased; this relationship was not altered by sometribove. "
08/01/1994 - "Increases in mastitis related to milk yield increase from sometribove or related to genetic selection were similar. "
08/01/1995 - "Superficial laceration of the tarsus (odds ratio [OR] = 2.1) and superficial swelling of the metatarsophalangeal joint (OR = 4.5) were positively associated with sometribove treatment, whereas femoral lesions (OR = 0.2) and superficial lacerations of the femur (OR = 0.14) were negatively associated with sometribove treatment."
|1.||Growth Hormone (Somatotropin)